Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are $39.69 Billion USD. In 2023 the company made an earning of $15.42 Billion USD, an increase over its 2022 earnings that were of $9.78 Billion USD. The earnings displayed on this page is the company's Pretax Income.